此页面是自动翻译的,不保证翻译的准确性。请参阅 英文版 对于源文本。

研究肾脏损害的参与者的静脉注射头孢菌素/切鲁伯龙的安全性和药代动力学的研究

2026年9月22日 更新者:Qpex Biopharma, Inc.

一项1阶段的开放标签,单剂量研究,以确定静脉注射头孢菌素/Xeruborbactam的安全性和药代动力学(S-649228)

A Phase 1, Open-label, Single-dose Study to Determine the Safety and Pharmacokinetics of Intravenous Cefiderocol/Xeruborbactam (S-649228) in Participants with Renal Impairment

研究概览

地位

完全的

条件

详细说明

Qpex Biopharma, Inc., a wholly owned subsidiary of Shionogi Inc., is developing a fixed combination antibiotic of cefiderocol, a cephalosporin antibiotic approved in the US for the treatment of complicated urinary tract infections (cUTIs) including pyelonephritis, and hospital-acquired bacterial pneumonia (HABP) and ventilator-associated bacterial pneumonia (VABP), plus an investigational broad-spectrum beta-lactamase inhibitor (BLI), xeruborbactam (QPX7728) to address the need for new antibiotics for the pathogens deemed as urgent or critical threats.

The aim of this study is to compare single-dose intravenous (IV) pharmacokinetics (PK) and safety of the combination of cefiderocol/xeruborbactam (S-649228) in participants with various degrees of stable renal impairment, including those with end-stage renal disease (ESRD), to control participants with normal renal function.

The results from this study will enable the development of appropriate dosing recommendations in patients with impaired renal function.

Objectives:

The objectives of the study are:

  1. To assess the impact of mild, moderate, and severe renal impairment, and intermittent hemodialysis (IHD) on the PK of IV cefiderocol and IV xeruborbactam given to participants with stable renal impairment, normal renal function, and ESRD receiving IHD therapy.
  2. To evaluate the safety and tolerability of IV cefiderocol and IV xeruborbactam given to participants with stable renal impairment, normal renal function, and ESRD receiving IHD therapy.

研究类型

介入性

注册 (实际的)

40

阶段

  • 阶段1

联系人和位置

本节提供了进行研究的人员的详细联系信息,以及有关进行该研究的地点的信息。

学习地点

    • Florida
      • Miami、Florida、美国、33136
        • University of Miami Clinical Pharmacology
      • Orlando、Florida、美国、32809
        • Orlando Clinical Research Center

参与标准

研究人员寻找符合特定描述的人,称为资格标准。这些标准的一些例子是一个人的一般健康状况或先前的治疗。

资格标准

适合学习的年龄

18年 至 80年 (成人、年长者)

接受健康志愿者

是的

有资格学习的性别

全部

描述

Inclusion Criteria:

An individual will be eligible to be included in the study only if all of the following criteria apply:

All participants

  • Able to understand the study conduct and tasks required of the participants, sign the informed consent form and willing to cooperate with all tests and examinations required by the protocol.
  • Aged 18 to 80 years, inclusive, at the time of consent.
  • If male, agrees to be sexually abstinent or agrees to use 2 approved methods of contraception (refer to Inclusion Criterion 4) when engaging in heterosexual activity from Day -1 through 90 days following the last administration of the study intervention, and to not donate sperm during this same period of time. If the sexual partner is surgically sterile, contraception is not necessary.
  • If female of childbearing potential, must either be sexually abstinent for 14 days prior to Day -1 and remain so through 30 days following dosing of the study intervention or have been using (or agree to use) 2 acceptable methods of birth control when engaging in heterosexual activity
  • If female of childbearing potential, must agree not to donate eggs (ova, oocytes) for the purpose of reproduction from Day -1 through 30 days following the last administration of the study intervention.
  • If female of non-childbearing potential, must either be postmenopausal (defined as 12 months spontaneous amenorrhea) with serum follicle stimulating hormone (FSH) level in the laboratory-defined postmenopausal range or have undergone sterilization procedures at least 6 months prior to Day -1; documentation of sterilization procedure must be obtained
  • Has a BMI ≥ 18.5 kg/m2 and ≤ 45 kg/m2, inclusive.
  • Has negative test results for hepatitis B surface antigen (HBsAg), anti-Hepatitis C virus (HCV) antibody, anti-human immunodeficiency virus (HIV) antibody, and SARS-CoV-2.

Participants with normal renal function:

  • Has an eGFR ≥ 90 mL/min calculated using the 2021 CKD-EPI equation adjusted for the participant's BSA at screening
  • Meets matching criteria for age, BMI, and gender of pooled renally impaired participants as defined in the protocol.

Participants with renal impairment

  • Stable mild to severe renal impairment, as assessed by eGFR calculated using the 2021 CKD-EPI equation adjusted for the participant's BSA at screening
  • Is on a stable medication regimen

Participants with ESRD on hemodialysis

  • Receiving stable IHD at least 3 times a week for at least 3 months, using an arteriovenous fistula, graft, or catheter
  • Is on a stable medication regimen

Exclusion Criteria:

An individual must not meet any of the following exclusion criteria to be eligible to participate in the study:

  • Has unstable or new medical condition(s)
  • Has had surgery under general anesthesia within the past 3 months prior to Day -1, determined by the investigator to be clinically relevant.
  • Documented hypersensitivity reaction or anaphylaxis to any medication.
  • History of seizures, convulsions
  • Current evidence or history of malignancy
  • If female, is pregnant, lactating, or has a positive pregnancy test at screening or Day -1.
  • Received any investigational drug within 30 days or 5 half-lives, whichever is longer, of Day -1 for the current clinical study.
  • Blood donation or significant blood loss (ie, > 500 mL) within 56 days prior to Day -1.
  • Plasma or platelet donation within 14 days prior to Day -1.
  • Any acute illness requiring antibiotic drug therapy within 30 days prior to Day -1 or a febrile illness within 7 days prior to Day -1.
  • Vigorous exercise from 72 hours prior to Day -1 through the final FU/EOS Visit.
  • Positive drug test at the Screening Visit or Day -1
  • Positive alcohol test at screening or Day -1 and/or recent history (ie, within 6 months prior to Day -1) of excessive alcohol intake.
  • Concurrent use of medications known to affect the elimination of serum creatinine and competitors of renal tubular secretion
  • Employees of the investigative site involved in this study.
  • Unable or unwilling to adhere to the study-specified procedures and restrictions.
  • QTcF interval > 500 msec, previous history or family history of prolonged QT syndrome at screening or Day -1.
  • Use of products containing alcohol, caffeine, xanthine, or ephedrine within 24 hours prior to Day -1; use of alcohol 48 hours prior to Day -1; use of proton pump inhibitors (eg, omeprazole and pantoprazole) 7 days prior to Day -1, including both over-the-counter (OTC) and prescription drugs in these categories; or consumption of grapefruit/grapefruit juice, Seville oranges, pomelo, exotic citrus fruits or grapefruit hybrids or juices containing such products within 7 days prior to Day -1.
  • Has any clinically significant abnormalities in laboratory values at screening or Day -1, defined in the study protocol.

Participants with normal renal function:

• Abnormal and clinically significant findings on physical examination, medical history, serum chemistry, hematology, or urinalysis per Investigator discretion.

Participants with renal impairment, including those on IHD:

  • Abnormal and clinically significant findings on physical examination, medical history, serum chemistry, hematology, or urinalysis per Investigator discretion. Participants in the renal impairment group will have consideration for the degree of renal impairment and presence of comorbidities.
  • Has renal disease secondary to hepatic disease (hepatorenal syndrome)

学习计划

本节提供研究计划的详细信息,包括研究的设计方式和研究的衡量标准。

研究是如何设计的?

设计细节

  • 主要用途:治疗
  • 分配:不适用
  • 介入模型:顺序分配
  • 屏蔽:无(打开标签)

武器和干预

参与者组/臂
干预/治疗
实验性的:Open Label, Single Dose of IV Cefiderocol/Xeruborbactam

Approximately 40 participants will be enrolled in total. Eight participants will be enrolled in each group (G) based on renal impairment (RI) determined by estimated glomerular function rate (eGFR) or need for intermittent hemodialysis (IHD) at screening:

  • G1: Mild RI (eGFR 60 < 90 mL/min calculated using the 2021 Chronic Kidney Disease Epidemiology Collaboration equation [CKP-EPI]) adjusted for the participant's body surface [BSA])
  • G2: Moderate RI (eGFR 30 to < 60 mL/min calculated using the 2021 CKD-EPI equation adjusted for the participant's BSA)
  • G3: Severe RI (eGFR < 30 mL/min calculated using the 2021 CKD-EPI equation) not receiving IHD therapy
  • G4: Healthy participants with normal renal function matched to participants in Groups 1 and 2 (Group 3 may be included) based on age, gender and body mass index (BMI)
  • G5: Participants with end stage renal disease (ESRD) receiving IHD

All participants will receive a single dose of cefiderocol/xeruborbactam on Day 1.

A fixed dose combination of intravenous cefiderocol and intravenous xeruborbactam

其他名称:
  • Cefiderocol/QPX7728
  • S-649228

研究衡量的是什么?

主要结果指标

结果测量
措施说明
大体时间
Incidence of treatment-emergent adverse events (TEAEs) by participant and by group
大体时间:11-22 days (+/- 2)

Number of participants with treatment-emergent adverse events by severity and relationship to treatment

11-22 days (+/- 2)
Number of participants with changes from baseline in safety parameters
大体时间:11-22 days (+/- 2)

Number of participants with changes in safety parameters before and after dosing by subject and group

11-22 days (+/- 2)
Maximum plasma concentration measurements by subject and by group (Cmax)
大体时间:11-22 days (+/- 2)

Comparison will be performed between the groups for maximum plasma concentration (Cmax).

11-22 days (+/- 2)
Time to maximum plasma concentration (Tmax)
大体时间:11-22 days (+/- 2)

Comparison will be performed between the groups for time to maximum plasma concentration (Tmax)

11-22 days (+/- 2)
Area under the plasma concentration versus time curve (AUC)
大体时间:11-22 days (+/- 2)

Comparison will be performed between the groups for area under the plasma concentration versus time curve (AUC)

11-22 days (+/- 2)
Cumulative amount of drug excreted as unchanged in the urine (Aeu)
大体时间:11-22 days (+/- 2)

This parameter will not be estimated in Group 5

11-22 days (+/- 2)
Cumulative amount of drug excreted as unchanged in the dialysate (Aed)
大体时间:11-22 days (+/- 2)

This parameter will be estimated only in Group 5. Urine pharmacokinetic (PK) parameters will be calculated from urinary excretion and dialysate data.

11-22 days (+/- 2)

合作者和调查者

在这里您可以找到参与这项研究的人员和组织。

调查人员

  • 首席研究员:Richard Preston, MD、University of Miami
  • 首席研究员:Thomas Marbury, MD、Orlando Clinical Research Center

研究记录日期

这些日期跟踪向 ClinicalTrials.gov 提交研究记录和摘要结果的进度。研究记录和报告的结果由国家医学图书馆 (NLM) 审查,以确保它们在发布到公共网站之前符合特定的质量控制标准。

研究主要日期

学习开始 (实际的)

2025年9月16日

初级完成 (实际的)

2026年9月4日

研究完成 (实际的)

2026年9月4日

研究注册日期

首次提交

2025年7月29日

首先提交符合 QC 标准的

2025年7月29日

首次发布 (实际的)

2025年8月5日

研究记录更新

最后更新发布 (实际的)

2026年9月25日

上次提交的符合 QC 标准的更新

2026年9月22日

最后验证

2026年9月1日

更多信息

与本研究相关的术语

计划个人参与者数据 (IPD)

计划共享个人参与者数据 (IPD)?

不

药物和器械信息、研究文件

研究美国 FDA 监管的药品

是的

研究美国 FDA 监管的设备产品

不

此信息直接从 clinicaltrials.gov 网站检索,没有任何更改。如果您有任何更改、删除或更新研究详细信息的请求,请联系 register@clinicaltrials.gov. clinicaltrials.gov 上实施更改,我们的网站上也会自动更新.

订阅